MGTA Stock Price, Magenta Therapeutics, . Quote, Chart

MGTA Stock Price

View Fullscreen

MGTA RSI Chart

MGTA Valuation

Market Cap

11.0M

Price/Earnings (Trailing)

-0.25

Price/Sales (Trailing)

1.07

Price/Free Cashflow

-0.3

MGTA Price/Sales (Trailing)

MGTA Profitability

Return on Equity

-25.82%

Return on Assets

-24.3%

Free Cashflow Yield

-337.97%

MGTA Fundamentals

MGTA Revenue

Revenue (TTM)

10.3M

Rev. Growth (Yr)

-21.23%

Rev. Growth (Qtr)

-77.41%

MGTA Earnings

Earnings (TTM)

-43.6M

Earnings Growth (Yr)

-4.86%

Earnings Growth (Qtr)

28.14%

Breaking Down MGTA Revenue

Last 7 days

-0.2%

Last 30 days

-7.2%

Last 90 days

4.1%

Trailing 12 Months

-57.7%

How does MGTA drawdown profile look like?

MGTA Financial Health

Current Ratio

18.42

MGTA Investor Care

Buy Backs (1Y)

75.53%

Diluted EPS (TTM)

-1.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.3M	10.6M	10.3M	0
2022	2.4M	3.4M	4.3M	5.2M
2021	4.0M	3.5M	3.6M	1.5M
2020	5.9M	0	5.0M	4.2M
2019	3.8M	5.1M	6.1M	6.2M
2018	789.0K	1.3M	1.9M	2.4M
2017	0	0	0	236.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Magenta Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 08, 2023	third rock ventures iv, l.p.	sold	-1,230,000	0.82	-1,500,000	-
Feb 07, 2023	third rock ventures iv, l.p.	sold	-1,826,000	0.83	-2,200,000	-
Nov 30, 2022	gardner jason	acquired	2,820	0.94	3,000	see remarks
Nov 30, 2022	beetham thomas w.	acquired	2,820	0.94	3,000	see remarks
Nov 30, 2022	mahoney stephen f.	acquired	2,820	0.94	3,000	see remarks
Nov 30, 2022	stants kristen	acquired	2,820	0.94	3,000	chief people officer
Nov 30, 2022	deardorf caren	acquired	2,820	0.94	3,000	chief commercial officer
May 31, 2022	gardner jason	acquired	2,970	0.99	3,000	see remarks
May 31, 2022	deardorf caren	acquired	2,970	0.99	3,000	chief commercial officer
May 31, 2022	beetham thomas w.	acquired	2,970	0.99	3,000	see remarks

Which funds bought or sold MGTA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 14, 2023	Axiom Investment Management LLC	sold off	-100	-1,000	-	-%
Jan 20, 2023	HELLMAN JORDAN MANAGEMENT CO INC /MA/	added	142	-83,000	174,000	0.30%
Nov 14, 2022	BREWIN DOLPHIN WEALTH MANAGEMENT LTD	unchanged	-	-2,000	2,000	-%
Sep 09, 2022	B. Riley Wealth Management, Inc.	new	-	13.00	13.00	-%
May 16, 2022	Amalgamated Financial Corp.	new	-	14,000	14,000	-%
May 16, 2022	Parametric Portfolio Associates LLC	new	-	61,000	61,000	-%

Are Funds Buying or Selling MGTA?

Are funds buying MGTA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MGTA

No. of Funds

Unveiling Magenta Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	fairmount funds management llc	9.99%	2,950,487	SC 13D/A
Feb 14, 2024	5am partners vii, llc	4.1%	1,199,228	SC 13G/A
Feb 14, 2024	third rock ventures iv, l.p.	0%	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 09, 2024	gv 2016, l.p.	1.4%	208,697	SC 13G/A
Feb 02, 2024	bcls fund iii investments, lp	9.99%	2,992,028	SC 13G
Feb 02, 2024	ra capital management, l.p.	9.99%	2,995,023	SC 13G
Jan 31, 2024	avidity partners management lp	9.9%	2,922,823	SC 13D
Jan 24, 2024	fairmount funds management llc	9.9%	2,947,317	SC 13D/A
Sep 21, 2023	5am partners vii, llc	7.1%	1,049,030	SC 13G

Recent SEC filings of Magenta Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	SC 13D/A	13D - Major Acquisition
Mar 27, 2024	EFFECT	EFFECT
Mar 21, 2024	10-K	Annual Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	S-1/A	Initial Public Offering
Mar 21, 2024	S-8	Employee Benefits Plan

Magenta Therapeutics, Inc. News

Latest updates

Magenta Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-77.4%	924	4,091	2,960	2,362	1,173	812	884	851	818	682	1,208	897	703	1,233	1,400	1,654	1,630	1,516	1,251	687	365
Operating Expenses	126.2%	16,683	7,375	32,130	-1,677	9,427	18,083	23,834	-39,990	18,245	17,610	18,697	19,065	18,381	21,244	24,637	22,644	19,338	16,350	17,930	16,702	14,025
S&GA Expenses	64.0%	8,723	5,318	6,132	-3,598	2,209	6,480	7,287	-18,944	7,450	6,481	6,969	6,809	6,595	7,281	5,923	6,120	5,905	5,813	5,540	5,284	4,342
R&D Expenses	5626.6%	7,960	139	7,995	1,921	7,218	11,603	16,547	-21,046	10,795	11,129	11,728	12,256	11,786	13,963	18,714	16,524	13,433	10,537	12,390	11,418	9,683
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-32.5%	-14,763	-11,140	-7,089	-10,116	-7,784	-5,695	-4,881	38,735	-17,427	-16,928	-17,489	-18,168	-17,678	-20,011	-23,237	-20,990	-17,708	-14,834	-16,679	-16,015	-13,660
Net Income Margin	-22.2%	-4.17*	-3.41*	-4.20*	-5.44*	4.75*	3.20*	-0.21*	-8.88*	-19.42*	-20.13*	-17.92*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	361.9%	17,136	-6,544	-35,844	-8,851	16,217	-16,982	-19,768	33,922	-15,198	-13,111	-16,781	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.8%	179	192	79.00	83.00	83.00	164	175	194	200	206	220	145	162	175	191	144	162	177	195	148	157
Current Assets	-7.3%	177	191	79.00	83.00	82.00	132	142	160	9.00	196	210	135	152	164	180	133	150	165	183	135	145
Cash Equivalents	-15.8%	132	157	63.00	49.00	15.00	37.00	57.00	74.00	8.00	159	157	51.00	3.00	143	138	77.00	67.00	87.00	35.00	33.00	60.00
Net PPE	-5.1%	0.00	0.00	-	-	0.00	6.00	7.00	7.00	0.00	8.00	8.00	8.00	8.00	9.00	9.00	10.00	10.00	10.00	11.00	11.00	10.00
Liabilities	-25.2%	11.00	14.00	4.00	6.00	9.00	40.00	39.00	43.00	5.00	17.00	17.00	16.00	18.00	16.00	17.00	19.00	20.00	16.00	16.00	14.00	12.00
Current Liabilities	-26.4%	10.00	13.00	4.00	6.00	8.00	13.00	11.00	14.00	5.00	10.00	11.00	9.00	11.00	10.00	10.00	13.00	14.00	10.00	10.00	8.00	10.00
Shareholder's Equity	-5.3%	169	178	75.00	77.00	106	124	136	151	173	190	203	129	144	159	174	125	141	162	180	134	146
Retained Earnings	-13.3%	-89.42	-78.90	-434	-431	-45.87	-78.90	-365	-348	-17.39	-306	-288	-271	-254	-236	-218	-199	-179	-156	-135	-117	-102
Additional Paid-In Capital	0.4%	258	257	509	509	2.00	506	502	500	0.00	496	492	401	398	395	392	325	321	318	315	251	248
Shares Outstanding	0.0%	15.00	15.00	61.00	61.00	-	61.00	59.00	59.00	-	54.00	51.00	49.00	49.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	56.30*	-	-	-	436	-	-	-	246	-	-	-	364	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-169.2%	-11,854	17,136	-6,544	-35,599	-8,851	16,375	-16,853	-19,741	33,937	-14,067	-13,000	-16,774	-13,733	-14,428	-19,205	-16,657	-15,627	-11,507	-15,033	-14,936	-12,624
Share Based Compensation	-42.0%	726	1,252	416	506	513	-2,745	1,845	1,905	-8,062	3,799	2,134	2,192	2,331	2,366	2,504	2,740	2,062	2,762	2,600	2,577	2,551
Cashflow From Investing	51.2%	-8,237	-16,880	18,874	26,496	-12,665	-6,881	-129	-40,144	-53,784	16,369	29,889	7,493	-70,974	19,980	14,964	25,395	-5,723	63,808	-43,822	-12,731	-88,394
Cashflow From Financing	-103.5%	-4,865	138,439	-	-	-	96,627	49.00	-	-74,565	203	88,856	418	1,179	-159	65,595	1,124	914	95.00	60,725	563	-476

MGTA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 32,841	$ 29,379
General and administrative	18,159	6,743
Total operating expenses	51,000	36,122
Loss from operations	(48,174)	(29,705)
Other income/(expense):
Interest income	4,764	1,145
(Loss)/gain on currency exchange, net	(85)	136
Other expense	(60)	(52)
Total other income	4,619	1,229
Net loss	$ (43,555)	$ (28,476)
Net loss per share attributable to common stockholders, basic	$ (8.45)	$ (32.57)
Net loss per share attributable to common stockholders, diluted	$ (8.45)	$ (32.57)
Weighted-average number of share of common stock outstanding, used in computing net loss per share of commonstock, basic	5,153,423	874,234
Weighted-average number of share of common stock outstanding, used in computing net loss per share of commonstock, diluted	5,153,423	874,234
Comprehensive loss:
Net Income (Loss)	$ (43,555)	$ (28,476)
Other comprehensive income/(loss):
Change in unrealized gains/(losses) related to available-for-sale debt securities	208	(161)
Total other comprehensive income/(loss)	208	(161)
Total comprehensive loss	(43,347)	(28,637)
Related Party [Member]
Revenues:
License revenue - related party	$ 2,826	$ 6,417

MGTA Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 132,325	$ 15,365
Short-term investments	41,393	60,125
Receivable from related party	294	4,700
Unbilled receivable from related party	184	938
Prepaid expenses and other current assets	3,255	905
Total current assets	177,451	82,033
Property and equipment, net	185	142
Right-of-use operating lease assets	615	814
Other assets and restricted cash	1,154	121
Total assets	179,405	83,110
Current liabilities:
Accounts payable	2,610	1,167
Accrued expenses	6,504	6,608
Current portion of deferred revenue - related party	100	100
Current portion of operating lease liabilities	417	350
Total current liabilities	9,631	8,225
Deferred revenue - related party	736	791
Long-term operating lease liabilities	168	438
Total liabilities	10,535	9,454
Commitments and contingencies (Note 16)
Convertible preferred stock; $0.0001 par value per share; authorized shares -none and 33,336,283 at December 31, 2023 and 2022, respectively; issued and outstanding - none and 33,336,282 at December 31, 2023 and 2022, respectively; liquidation preference - none and $121,500 at December 31, 2023 and 2022, respectively	0	118,024
Stockholders' equity/(deficit):
Preferred stock; $0.001 par value per share; authorized shares - 10,000,000 and none at December 31, 2023 and 2022, respectively; issued and outstanding - none at December 31, 2023 and 2022	0	0
Common stock; par value per share-$0.001 and $0.0001 at December 31, 2023 and 2022, respectively; authorized shares - 150,000,000 and 8,722,279 at December 31, 2023 and 2022, respectively; issued and outstanding shares-14,817,696 and 875,279 at December 31, 2023 and 2022, respectively	15	0
Additional paid-in capital	258,231	1,661
Accumulated deficit	(89,423)	(45,868)
Accumulated other comprehensive income/(loss)	47	(161)
Total stockholders' equity/(deficit)	168,870	(44,368)
Total liabilities, convertible preferred stock and stockholders' equity/(deficit)	$ 179,405	$ 83,110

About Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Magenta Therapeutics, Inc.? What does MGTA stand for in stocks?

MGTA is the stock ticker symbol of Magenta Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Magenta Therapeutics, Inc. (MGTA)?

As of Sun Dec 31 2023, market cap of Magenta Therapeutics, Inc. is 11.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MGTA stock?

You can check MGTA's fair value in chart for subscribers.

What is the fair value of MGTA stock?

You can check MGTA's fair value in chart for subscribers. The fair value of Magenta Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Magenta Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MGTA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Magenta Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether MGTA is over valued or under valued. Whether Magenta Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Magenta Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MGTA.

What is Magenta Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Sun Dec 31 2023, MGTA's PE ratio (Price to Earnings) is -0.25 and Price to Sales (PS) ratio is 1.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MGTA PE ratio will change depending on the future growth rate expectations of investors.